Announcement • Jun 01

Scienture Holdings, Inc. Announces CFO Changes, Effective May 26, 2026

Scienture Holdings, Inc. announced that Eric Sherb, the Chief Financial Officer (CFO), formally resigned his position as CFO and advised the Company that his resignation was due to personal reasons and not a result of any dispute or disagreement with the Company, its management, or its board of directors. Scienture Holdings, Inc. appointed Dr. Narasimhan Mani (age 51) to serve as the Company's Interim Chief Financial Officer (Interim CFO) effective as of May 26, 2026. Dr. Mani has served as a director and the Co-Chief Executive Officer and President of the Company since May 2025. Dr. Mani has, among others, led, managed, and overseen the Company's operations, including its financial operations such as revenue and expense management, financial planning and analysis, and financial reporting. Dr. Mani is an experienced healthcare professional, having been employed in the pharmaceutical industry for over 25 years with many of those in senior management positions. In addition to Dr. Mani's technical pharmaceutical experience, he has served in various financial-focused roles for life sciences companies and holds an MBA in Finance and Marketing from Columbia Business School. Prior to joining the Company, Dr. Mani served as the President and Chief Executive Officer for Kesin Pharma Corporation, a specialty pharma company with a focus on commercializing specialty and brand products. His past roles include serving as the Chief Executive Officer of Xiromed LLC, a generics and specialty drug product company and as the Vice President, Global Corporate Strategy and Business Development, at Amneal Pharmaceuticals where he led all the company's strategic initiatives across Global Strategy, Portfolio Management, Business Development, and Commercial Operations. His previous experiences also include being the Corporate Finance and Strategic Planning Leader at Johnson & Johnson in New Brunswick, New Jersey, in the pharmaceutical and medical device sectors. He also worked as a Research Scientist and Product Development leader during his time at Forest Laboratories and Par Pharmaceuticals. He is an invited member of the Executives-in-Residence at New Rhein Healthcare Investors, a life-sciences focused private equity firm, and serves on the board of directors at Corsair Pharma, Inc., one of their portfolio companies. Dr. Mani's journey in the pharmaceutical and healthcare space began with his B.Pharm (Hons.) from BITS, Pilani, India which he completed in 1995. His subsequent graduate degrees include M.S. Analytical Chemistry, from the University of Oklahoma, Norman in 1998, Ph.D. in Pharmaceutics, from the University of Georgia, Athens in 2003 and his MBA in Finance and Marketing, from Columbia Business School, New York, NY in 2008. Dr. Mani is also the recipient of the 2021 Outstanding 50 Asian Americans in Business Award in September 2021.

Scienture Holdings, Inc. Stock Price

SCNX Share Price Performance

SCNX Community Narratives

Trending Discussion

Recently Updated Narratives

Snowflake Analysis

Scienture Holdings, Inc. Key Details

About SCNX

Recent SCNX News & Updates

Scienture Holdings, Inc. Announces CFO Changes, Effective May 26, 2026

First quarter 2026 earnings released: US$0.084 loss per share (vs US$0.33 loss in 1Q 2025)

Full year 2025 earnings: EPS and revenues miss analyst expectations

Recent updates

Scienture Holdings, Inc. Competitors

Elite Health Systems

NeuroOne Medical Technologies

Vivos

Cytosorbents